Kalkine has a fully transformed New Avatar.

Switch to Old version
1800-272-662
Shopping Cart 0
countryflagAU
Login

Zimmer Biomet Holdings Inc

Healthcare US ZBH

91.7USD
-1.58(1.69%)

Last update at 2026-03-10T20:00:00Z

Day Range

91.4993.65
LowHigh

52 Week Range

101.80148.38
LowHigh

Fundamentals

  • Previous Close 93.28
  • Market Cap25311.78M
  • Volume1967931
  • P/E Ratio53.59
  • Dividend Yield0.79%
  • EBITDA2383.40M
  • Revenue TTM7279.20M
  • Revenue Per Share TTM34.79
  • Gross Profit TTM 4920.40M
  • Diluted EPS TTM2.26

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax 403.50M 499.00M -274.40000M 905.80M -271.10000M
Minority interest -1.00000M -0.50000M 1.50M -0.10000M -0.10000M
Net income 231.40M 401.60M -137.40000M 1131.60M -379.20000M
Selling general administrative 2761.70M 3323.90M 3177.80M 3343.80M 3379.30M
Selling and marketing expenses - - - - -
Gross profit 4920.40M 4866.90M 4896.20M 5729.60M 5661.00M
Reconciled depreciation 926.40M 1067.40M 1032.70M 1006.10M 1040.50M
Ebit 1064.10M 860.30M 723.30M 1137.50M 1134.90M
Ebitda 1990.50M 1955.30M 1756.00M 2271.10M 2175.40M
Depreciation and amortization 926.40M 1095.00M 1032.70M 1133.60M 1040.50M
Non operating income net other -128.00000M -153.30000M 25.40M -4.80000M -15.60000M
Operating income 1064.10M 860.30M 723.30M 1137.50M 33.80M
Other operating expenses 5747.80M 5821.90M 6326.60M 6712.40M 6785.70M
Interest expense 164.80M 208.40M 212.00M 226.90M 292.60M
Tax provision 112.30M 16.30M -137.00000M -225.70000M 108.20M
Interest income 164.80M 208.40M 212.00M 237.90M 3.30M
Net interest income -164.80000M -208.40000M -212.00000M -226.90000M -289.30000M
Extraordinary items -58.80000M -30.10000M 5.00M 315.00M -8.30000M
Non recurring 292.80M 16.30M 645.00M 70.10M 979.70M
Other items - - - - -
Income tax expense 112.30M 53.50M -137.00000M -225.70000M 108.20M
Total revenue 6939.90M 6827.30M 7024.50M 7982.20M 7932.90M
Total operating expenses 3728.30M 3861.50M 4198.30M 4459.80M 4513.80M
Cost of revenue 2019.50M 1960.40M 2128.30M 2252.60M 2271.90M
Total other income expense net -660.60000M -361.30000M -997.70000M -231.70000M -1129.00000M
Discontinued operations -58.80000M -43.40000M -128.20000M -128.20000M -
Net income from continuing ops 291.20M 402.10M -137.40000M 1131.50M -379.30000M
Net income applicable to common shares 231.40M 401.60M -138.90000M 1131.60M -379.20000M
Preferred stock and other adjustments - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 21066.00M 23456.40M 24417.70M 24638.70M 24126.80M
Intangible assets 5063.80M 5533.60M 7055.50M 7257.60M 7684.60M
Earning assets - - - - -
Other current assets 522.90M 607.10M 377.80M 357.10M 352.30M
Total liab 9039.00M 10790.00M 12218.30M 12245.90M 12850.70M
Total stockholder equity 12021.30M 12660.70M 12199.40M 12392.80M 11276.10M
Deferred long term liab 474.80M 665.60M 790.40M 840.10M 999.50M
Other current liab 985.00M 511.00M 1581.90M 1941.50M 1896.30M
Common stock 3.10M 3.10M 3.10M 3.10M 3.10M
Capital stock 3.10M 3.10M 3.10M 3.10M 3.10M
Retained earnings 9559.30M 10292.20M 10086.90M 10427.30M 9491.20M
Other liab 1143.00M 1858.40M 2034.90M 1867.50M 2013.20M
Good will 8580.20M 8919.40M 9261.80M 9599.70M 9594.40M
Other assets 1122.20M 1062.90M 969.40M 652.90M 387.10M
Cash 375.70M 378.10M 802.10M 617.90M 542.80M
Cash and equivalents 375.70M 478.50M 802.10M 617.90M 542.80M
Total current liabilities 2358.20M 3467.90M 2556.90M 3441.50M 2396.30M
Current deferred revenue 474.80M 1045.30M 145.00M -400.90000M -362.60000M
Net debt 5320.80M 6701.20M 7324.40M 7603.50M 8395.90M
Short term debt 544.30M 1605.10M 500.00M 1500.00M 500.00M
Short long term debt 544.30M 1605.10M 500.00M 1500.00M 525.00M
Short long term debt total 5696.50M 7079.30M 8126.50M 8221.40M 8938.70M
Other stockholder equity 2638.20M 2597.00M 2407.20M 2204.30M 1969.20M
Property plant equipment 1872.50M 2016.50M 2047.70M 2077.40M 2015.40M
Total current assets 4427.30M 4885.00M 5083.30M 4723.90M 4427.40M
Long term investments - - - 60.50M 17.90M
Net tangible assets -1623.70000M -2825.60000M -4123.10000M -4469.20000M -6007.70000M
Short term investments - - - - -
Net receivables 1381.50M 1259.60M 1452.70M 1363.90M 1275.80M
Long term debt 5152.20M 5463.70M 7626.50M 6721.40M 8413.70M
Inventory 2147.20M 2148.00M 2450.70M 2385.00M 2256.50M
Accounts payable 354.10M 306.50M 330.00M 400.90M 362.60M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity 6.70M 5.70M 5.20M 4.70M 4.80M
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -179.30000M -231.60000M -297.80000M -241.90000M -187.40000M
Additional paid in capital - - - - -
Common stock total equity 3.10M 3.10M 3.10M 3.10M 3.10M
Preferred stock total equity - - - - -
Retained earnings total equity 9559.30M 10292.20M 10086.90M 10427.30M 9491.20M
Treasury stock -6867.20000M -6717.80000M -6719.60000M -6720.50000M -6721.70000M
Accumulated amortization - - - - -
Non currrent assets other 647.40M 2281.80M 969.40M 980.10M 405.00M
Deferred long term asset charges - - - - -
Non current assets total 16638.70M 18571.40M 19334.40M 19914.80M 19699.40M
Capital lease obligations - - - - -
Long term debt total 5152.20M 5463.70M 7626.50M 6721.40M 8413.70M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -529.20000M -503.60000M 53.50M 48.10M 69.20M
Change to liabilities -49.90000M 76.40M -386.20000M 69.40M 5.10M
Total cashflows from investing activities -529.20000M -503.60000M -613.80000M -729.30000M -416.60000M
Net borrowings -1062.30000M -1055.00000M -275.20000M -716.10000M -1154.40000M
Total cash from financing activities -843.80000M -1306.00000M -421.80000M -779.90000M -1302.20000M
Change to operating activities -1.20000M -44.20000M 69.50M -17.90000M 8.40M
Net income 291.20M 445.50M -137.40000M 1131.50M -379.30000M
Change in cash -102.80000M -323.60000M 184.20M 75.10M 18.40M
Begin period cash flow 478.50M 802.10M 617.90M 542.80M 524.40M
End period cash flow 375.70M 478.50M 802.10M 617.90M 542.80M
Total cash from operating activities 1284.70M 1499.20M 1204.50M 1585.80M 1747.40M
Issuance of capital stock - - - - -
Depreciation 926.40M 937.70M 1032.70M 1006.10M 1040.50M
Other cashflows from investing activities -83.00000M -29.80000M -549.80000M -570.30000M -323.10000M
Dividends paid -201.20000M -200.10000M -198.50000M -196.70000M 195.20M
Change to inventory -75.60000M -8.40000M -40.80000M -125.20000M -199.50000M
Change to account receivables -184.70000M -15.10000M -349.10000M -521.10000M 213.60M
Sale purchase of stock -126.40000M 122.50M 129.80M 158.20M 107.90M
Other cashflows from financing activities 1222.50M 1548.90M 1526.70M 882.10M 1871.90M
Change to netincome 378.50M 267.20M 736.70M -384.30000M 1058.60M
Capital expenditures 187.90M 152.00M 117.90M 404.70M 162.70M
Change receivables -184.70000M -15.10000M -70.00000M -93.80000M 213.60M
Cash flows other operating 290.00M -44.20000M 69.50M -17.90000M 8.40M
Exchange rate changes - - - - -
Cash and cash equivalents changes 58.50M -310.40000M 168.90M 76.60M 28.60M
Change in working capital -311.40000M -134.20000M -415.50000M -706.20000M 41.00M
Stock based compensation 105.00M 76.00M 79.70M 84.30M 65.50M
Other non cash items 337.90M 276.30M 633.00M 608.80M 966.30M
Free cash flow 1096.80M 1347.20M 1086.60M 1181.10M 1584.70M

Peer Comparison

Sector: Healthcare Industry: Medical Devices

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
ZBH
Zimmer Biomet Holdings Inc		 -1.58 1.69% 91.70 53.59 15.08 3.44 2.00 4.18 16.55
ABT
Abbott Laboratories		 -2.1 1.86% 110.55 37.15 23.15 4.67 4.97 4.88 19.38
SYK
Stryker Corporation		 -7.27 1.99% 358.65 44.07 24.94 5.51 6.12 6.05 25.73
MDT
Medtronic PLC		 -1.45 1.59% 89.89 26.60 15.87 3.35 2.08 3.90 14.12
BSX
Boston Scientific Corp		 -1.94 2.70% 69.96 68.17 24.57 5.85 4.26 6.46 26.80

Reports Covered

Stock Research & News

View All

Profile

Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company designs, manufactures, and markets orthopaedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It also offers robotic, surgical, and bone cement products. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopaedic surgeons, neurosurgeons, hospitals, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.

Zimmer Biomet Holdings Inc

345 East Main Street, Warsaw, IN, United States, 46580

Key Executives

Name Title Year Born
Mr. Bryan C. Hanson Chairman, Pres & CEO 1967
Mr. Suketu P. Upadhyay Exec. VP & CFO 1969
Mr. Ivan Tornos Chief Operating Officer 1976
Mr. Sang Yi Group Pres of Asia Pacific 1962
Mr. Wilfred van Zuilen Pres of Europe, Middle East & Africa NA
Mr. Paul A. Stellato VP, Controller & Chief Accounting Officer 1975
Dr. Nitin Goyal M.D. Chief Science, Technology & Innovation Officer NA
Mr. Zeeshan Tariq Sr. VP & Chief Information Officer NA
Ms. Keri P. Mattox Chief Communications & Admin. Officer and Sr. VP of Investor Relations NA
Mr. Chad F. Phipps Sr. VP, Gen. Counsel & Sec. 1972

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.